Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
Annovis Bio announced a collaboration with Weave Bio, an AI regulatory platform, to draft and manage documents for the planned NDA submission of buntanetap in Alzheimer's disease. The move prepares most of the NDA ahead of the 6-month top-line readout from the pivotal Phase 3 AD trial, which completed enrollment of 862 biomarker-confirmed patients, exceeding the 760 target.
Key figures
- Drug Name
- buntanetap
- Phase Of Trial
- Phase 3
- Database lock
- December 2026
- Top line data
- March 2027
- Patients enrolled
- 862
- Original enrollment target
- 760
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.